Biljana Lazovic, Rade Milic, Dzenana A Detanac, Vladimir Zugic, Džemail S Detanac, Mersudin Mulic


Pulmonary embolism (PE) and deep vein thrombosis (DVT) are associated with considerable morbidity and mortality, and for as much as twenty-five percent of PE patients the primary clinical appearance is unexpected death. Diagnosis of PE is based on clinical suspicious at first, but sometimes its diagnostics can be extremely difficult. Newly increased interest in an inherited thrombophilic states has been provoked by the discovery of several common inherited abnormalities, i.e. the prothrombin (PT) gene G20210A, Factor V Leiden (FVL) mutation (Arg506Gln), hyperhomocystenemia and homocysteiuria, Wein-Penzing defect, Sticky Platelet Syndrome (SPS), Quebec platelet disorder (QPD) and Sickle Cell Disease (SCD). PE incidence rates increase in recent years. The only explanation at this moment is increased awareness of PE, especially after any kind of surgery, immobile state or unexplained shorthness of breath.


: Inherited thrombophilic states, venous thromboembolism, pulmonary embolism

Full Text:



Rossi E, Za T, Ciminello A, Leone G, De Stefano V. The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. Thromb Haemost. 2008;99(6):1030–4.

Dahlbäck B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays. Pros and Cons Thromb Haemost. 1995; 73(5):739–42.

Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89(2):397–402.

Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1. Thromb Haemost. 1996; 76(5):651–62.

Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant responsce to activated protein C. Proc Natl AcadSci USA.1993; 90(3): 1004-8.

Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost. 1995; 74(4):1–6.

Kane WH, Davie EW. Blood coagulation factor V and VIII: structural and functional similarities and their relationship to haemorrhegic and thrombotic disorders. Blood. 1988; 71(3):539–55.

Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994; 269(50):31869–80.

Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to ctivated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90(3):1004-8.

Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde HD, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64–7.

Dahlbäck B. Resistance to activated protein C caused by the factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost. 1997;78:483–8.

Faioni EM, Razzari C, Martinelli I, Panzeri D, Franchi F, Mannucci PM. Resistance to activated protein C in unselected patients with arterial and venous thrombosis. Am J Hematol. 1997;55(2): 59–64.

Bontempo FA, Hassett AC, Faruki H Steed DL, Webster MW, Makaroun MS.. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg. 1997;25(2):271–5.

Samama MM, Simon D, Horellou MH, Trossaërt M, Elalamy I, Conard J. Diagnosis and clinical characteristics of inherited activated protein C resistance. Haemostasis. 1996;26(suppl 4):315- 30.

Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost. 1995; 74(3):996.

Calderwood C, Greer I. The role of factor V Leiden in maternal health and the outcome of pregnancy. Curr Drug Targets. 2005; 6(5):567–76.

Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133–4.

Schröder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in a northeastern German population. Haemostasis. 1996;26(5):233–6.

Perry DJ, Pasi KJ. Resistance to activated protein C and factor V Leiden. Q J Med. 1997; 90(6):379–85.

Castoldi E, Lunghi B, Mingozzi F, Ioannou P, Marchetti G, Bernardi F. New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V Leiden mutation in Mediterranean populations and Indians. Thromb Haemost. 1997; 78(3):1037–41.

Bauder F, Ducout L, Guerre C, Freyburger G. Activated protein C (APC) resistance: does it exist in Basques. Br J Haematol. 1997; 99(3):712–3.

Zabalegui N, Montes R, Orbe J, Ayape ML, Medarde A, Páramo JA, et al. Prevalence of FVR506Q and prothrombin 20210A mutations in the Navarrese population. Thromb Haemost. 1998;80(3):522–3.

Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis. 2001;27(2):362–7.

DOI: http://dx.doi.org/10.24125/sanamed.v14i1.286


  • There are currently no refbacks.

Copyright (c) 2019 biljana lazovic, rade milic, dzenana detanac, vladimir zugic

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.